| Publication date |
Media |
Title/Summary |
| Feb 01, 2014 |
Journal |
Iyaku Keizai, February 1, 2014 p.48～p.49 |
interview
Requesting reasonable NHI prices, the government should also be prepared |
| Dec 01, 2013 |
WEB |
Nikkei Biotech Online |
MHLW convenes the First Committee of
the Pharmaceutical Affairs Council approves
the approval of ReqMed’s Cystadan® bulk powder
On November 29, 2013, the Ministry of Health,
Labor and Welfare (MHLW) held the First Committee
of the Pharmaceutical Affairs and Food Sanitation
Council to deliberate and report on Cystadan® bulk
powder, an application filed by ReqMed, and other
drugs, and approved them all. |
| Aug 28, 2013 |
Newspaper |
Nikkan Yakugyo |
MHLW Notifies Generic Names of Drug Candidates
The Ministry of Health, Labour and Welfare’s
Pharmaceutical and Food Safety Bureau notified
prefectural governments of betaine as one of 11 drug
candidate compounds with a generic name (JAN) in
Japan on August 23.
|
| Jun 01, 2013 |
Journal |
NEW CURRENT June 1, 2013 (Vol. 24, No. 12) p.49 – p.50 |
Patent Information Digest of Drug and Compound
Patents “Pentosan Polysulfate
Pentosan polysulfate shows promise as a fundamental
treatment in clinical studies of HTLV-1-related
myelopathy
|
| Apr 05, 2013 |
Newspaper |
Nikkei Sangyo Shimbun |
Congenital disease drug ReqMed filed for
uremia, domestic production version.
Bio-venture company ReqMed (Machida City, Tokyo)
announced that it has applied for domestic
manufacturing and marketing approval of betaine
anhydrous (generic name) for the indication of
the congenital disease “homocystinuria”.
|
| Apr 04, 2013 |
WEB |
Nikkei Biotech Online |
ReqMed filed for approval of a new drug for homocystinuria, a rare disease with about 100 patients
in Japan.
On March 29, 2013, ReqMed (Machida City, Tokyo, President Tadashi Matsumoto) applied for manufacturing and marketing approval of Cystadan® bulk powder (betaine anhydride), a drug for homocystinuria.
|